DURECT Corp logo




Earnings Summary

Net Profits
Net Profit Margins



DURECT Corp’s revenue fell -20.98% since last year same period to $3.41Mn in the Q2 2018. On a quarterly growth basis, DURECT Corp has generated -2.15% fall in its revenue since last 3-months.

Net Profits:

DURECT Corp’s net profit jumped 29.37% since last year same period to $-7.01Mn in the Q2 2018. On a quarterly growth basis, DURECT Corp has generated 15.5% jump in its net profits since last 3-months.

Net Profit Margins:

DURECT Corp’s net profit margin jumped 10.63% since last year same period to -205.42% in the Q2 2018. On a quarterly growth basis, DURECT Corp has generated 13.64% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the DURECT Corp post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

DURECT Corp’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a -380% fall from last quarter’s estimates.

EPS Estimate Current Year:

DURECT Corp’s earning per share (EPS) estimates for the current year stand at -0.48.

Key Ratios

Key ratios of the DURECT Corp post its Q4 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. DURECT Corp’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. DURECT Corp’s return on equity (ROE) stands at -0.85.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.

10260 Bubb Road, Cupertino, CA, United States, 95014-4166
Health Technology
James Brown

Trading and brokerage services provided by

Alpaca iconDrivewealth icon

Banking and Remittance services provided by

SBM icon

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*